<DOC>
	<DOCNO>NCT02890381</DOCNO>
	<brief_summary>The purpose study evaluate safety , infectivity , immunogenicity single dose recombinant live-attenuated respiratory syncytial virus ( RSV ) vaccine RSV-seronegative infant 6 24 month age . This study companion study CIR 312 .</brief_summary>
	<brief_title>Evaluating Infectivity , Safety Immunogenicity Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine ( RSV LID cp ΔM2-2 ) RSV-Seronegative Infants 6 24 Months Age</brief_title>
	<detailed_description>Human respiratory syncytial virus ( RSV ) common viral cause serious acute lower respiratory illness ( LRI ) infants child 5 year age worldwide . This study evaluate safety , infectivity , immunogenicity single dose RSV LID cp ΔM2-2 , recombinant live-attenuated RSV vaccine , RSV-seronegative infant 6 24 month age . Participants randomly assign receive single dose RSV LID cp ΔM2-2 vaccine placebo study entry ( Day 0 ) . Participants enrol study April 1 October 14 ( outside RSV season ) remain study complete post-RSV season visit April 1 April 30 calendar year follow enrollment . Participants ' total study duration 6 10 month , depend enroll study . Participants attend several study visit throughout study , may include physical examination , blood collection , nasal wash . Participants ' parent guardian contact study staff various time study monitor participant ' health .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Greater equal 6 month ( define great equal 180 day ) age time screen less 25 month ( define less 750 day ) age . The participant good health base review medical record , history , physical examination , without evidence chronic disease . Parents/guardians willing able provide write informed consent describe protocol . Seronegative RSV antibody , define serum RSVneutralizing antibody titer le 1:40 screening sample collect 42 day prior inoculation . Note : result specimen collect screen IMPAACT 2011 acceptable long within 42day window . Is grow normal velocity age ( demonstrated standard growth chart ) AND If less 1 year age : current height weight 5th percentile . If 1 year age older : current height weight 3rd percentile age . Participant receive routine immunization appropriate age ( per national Center Disease Control Advisory Committee Immunization Practices [ ACIP ] ) . Participant expect available duration study . If bear HIVinfected woman , participant must breastfed must documentation 2 negative HIV nucleic acid ( RNA DNA ) test result sample collect different date collect great equal 1 month age least one collect great equal 4 month age , positive HIV nucleic acid ( RNA DNA ) test ; 2 negative HIV antibody test , sample collect great equal 6 month age . Known suspected HIV infection impairment immunological function . Receipt immunosuppressive therapy , include systemic , include either nasal inhale , corticosteroid within 28 day enrollment . Note : Cutaneous ( topical ) steroid treatment exclusion . Bone marrow/solid organ transplant recipient . Major congenital malformation ( congenital cleft palate ) cytogenetic abnormality . Previous receipt license investigational RSV vaccine ( placebo IMPAACT RSV study ) previous receipt plan administration antiRSV product ( ribavirin RSV IG RSV mAb ) . Previous anaphylactic reaction . Previous vaccineassociated adverse reaction Grade 3 . Known hypersensitivity study product component . Heart disease . Note : Participants cardiac abnormality document clinically insignificant require treatment may enrol . Lung disease , include history reactive airway disease medically document wheeze . Member household contains , contain , infant le 6 month age enrollment date Day 28 . Member household contain another child , schedule , enrol IMPAACT 2011 , 2012 2013 AND overlap residency child 's participation study 's Acute Phase ( Days 0 28 ) . Member household contains immunocompromised individual , include , limited : person great equal 6 year age HIVrelated immunodeficiency , define recent CD4 T lymphocyte cell count le 300 cells/mm^3 . CD4 T lymphocyte count must measure within 6 month prior enrollment , person age 1 year less 6 year HIVrelated immunodeficiency , define recent CD4 T lymphocyte cell percentage le 25 CD4 T lymphocyte count le 750 cells/mm^3 ( value available , use low two ) . CD4 T lymphocyte parameter must measure within 6 month prior enrollment ; person age less 1 year HIVrelated immunodeficiency , define recent CD4 T lymphocyte cell percentage le 30 CD4 T lymphocyte count less 1000 cells/mm^3 ( value available , use low two ) . CD4 T lymphocyte parameter must measure within 6 month prior enrollment ; person receive chemotherapy within 12 month prior enrollment ; person receive immunosuppressant agent ; person live solid organ bone marrow transplant . Verbal report CD4 T cell lymphocyte sufficient documentation parent/guardian confident history . Attends daycare facility share room infant less 6 month age , parent/guardian unable unwilling suspend daycare 28 day follow inoculation . Any following event time enrollment : fever ( rectal temperature great equal 100.4°F ( 38°C ) ) , upper respiratory sign symptom ( rhinorrhea , cough , pharyngitis ) nasal congestion significant enough interfere successful inoculation , otitis medium . Receipt follow prior enrollment : kill vaccine liveattenuated rotavirus vaccine within 14 day prior , live vaccine , rotavirus vaccine , within 28 day prior , another investigational vaccine investigational drug within 28 day prior Scheduled administration follow planned inoculation : kill vaccine liveattenuated rotavirus vaccine within 14 day , live vaccine rotavirus 28 day , another investigational vaccine investigational drug 56 day Receipt immunoglobulin , antibody product , blood product within past 6 month . Receipt follow medication within 3 day study enrollment : systemic antibacterial , antiviral , antifungal , antiparasitic , antituberculous agent , whether treatment prophylaxis , intranasal medication , prescription medication except list Permitted concomitant medication ( prescription nonprescription ) include nutritional supplement , medication gastroesophageal reflux , eye drop , topical medication , include ( limited ) cutaneous ( topical ) steroid , topical antibiotic , topical antifungal agent . Receipt salicylate ( aspirin ) salicylatecontaining product within 28 day prior enrollment . Born le 34 week gestation . Born le 37 week gestation le 1 year age time enrollment . Suspected documented developmental disorder , delay , developmental problem . Previous receipt supplemental oxygen therapy home setting .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>